Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal
Abstract Context The behavior of locally advanced pheochromocytoma (LAP) remains unknown. Objective We characterized the population with LAP and recurrence-free survival (RFS). Methods This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumor...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2021-09, Vol.106 (9), p.2726-2737 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2737 |
|---|---|
| container_issue | 9 |
| container_start_page | 2726 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 106 |
| creator | Moog, Sophie Castinetti, Frédéric DoCao, Christine Amar, Laurence Hadoux, Julien Lussey-Lepoutre, Charlotte Borson-Chazot, Françoise Vezzosi, Delphine Drui, Delphine Laboureau, Sandrine Raffin Sanson, Marie-Laure Lamartina, Livia Pierre, Peggy Batisse Ligner, Marie Hescot, Ségolène Al Ghuzlan, Abir Renaudin, Karine Libé, Rosella Laroche, Suzanne Deniziaut, Gabrielle Gimenez-Roqueplo, Anne-Paule Jannin, Arnaud Leboulleux, Sophie Guerin, Carole Faron, Matthieu Baudin, Eric |
| description | Abstract
Context
The behavior of locally advanced pheochromocytoma (LAP) remains unknown.
Objective
We characterized the population with LAP and recurrence-free survival (RFS).
Methods
This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence.
Results
Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis.
Conclusion
LAP represents 9% of pheochromocytoma’s population and has a metastatic behavior. This study paves the way for future pathological TNM classification. |
| doi_str_mv | 10.1210/clinem/dgab202 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03662818v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A688651769</galeid><oup_id>10.1210/clinem/dgab202</oup_id><sourcerecordid>A688651769</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-9232ef29c4123fe4a11ad3c685b5874f7ef3b083ed9c76c46ac2ca84f1d59bfc3</originalsourceid><addsrcrecordid>eNqF0c-L1DAUB_AiijuuXj1KwYseuptfzQ9vZXFcYUDxB3oLafqykyVtukk7MP-9HWZcRRYkh8Dj8x7J-xbFS4wuMMHo0gY_QH_Z3ZiWIPKoWGHF6kpgJR4XK4QIrpQgP8-KZznfIoQZq-nT4oxSIQlXYlX8-AJ2TgkGC9U6AZRf57TzOxPKZjBhn30u_VBuojUh7Mum25lFduXnLUS7TbGPdj_F3rwr1z7lqWzGMRmfTXhePHEmZHhxus-L7-v3366uq82nDx-vmk1lmZJTpQgl4IiyDBPqgBmMTUctl3VbS8GcAEdbJCl0ygpuGTeWWCOZw12tWmfpefH2OHdrgh6T703a62i8vm42-lBDlHMisdzhxb452jHFuxnypHufLYRgBohz1qRGAjNOqVzo63_obZzTspFFqZpjilT9l7oxAbQfXJySsYehuuFS8hoLrhZ18YBaTge9t3EA55f6Qw02xZwTuPuPYaQPqetj6vqU-tLw6vTaue2hu-e_Y_6zpTiP_xv2C5lwtkg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956130958</pqid></control><display><type>article</type><title>Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Moog, Sophie ; Castinetti, Frédéric ; DoCao, Christine ; Amar, Laurence ; Hadoux, Julien ; Lussey-Lepoutre, Charlotte ; Borson-Chazot, Françoise ; Vezzosi, Delphine ; Drui, Delphine ; Laboureau, Sandrine ; Raffin Sanson, Marie-Laure ; Lamartina, Livia ; Pierre, Peggy ; Batisse Ligner, Marie ; Hescot, Ségolène ; Al Ghuzlan, Abir ; Renaudin, Karine ; Libé, Rosella ; Laroche, Suzanne ; Deniziaut, Gabrielle ; Gimenez-Roqueplo, Anne-Paule ; Jannin, Arnaud ; Leboulleux, Sophie ; Guerin, Carole ; Faron, Matthieu ; Baudin, Eric</creator><creatorcontrib>Moog, Sophie ; Castinetti, Frédéric ; DoCao, Christine ; Amar, Laurence ; Hadoux, Julien ; Lussey-Lepoutre, Charlotte ; Borson-Chazot, Françoise ; Vezzosi, Delphine ; Drui, Delphine ; Laboureau, Sandrine ; Raffin Sanson, Marie-Laure ; Lamartina, Livia ; Pierre, Peggy ; Batisse Ligner, Marie ; Hescot, Ségolène ; Al Ghuzlan, Abir ; Renaudin, Karine ; Libé, Rosella ; Laroche, Suzanne ; Deniziaut, Gabrielle ; Gimenez-Roqueplo, Anne-Paule ; Jannin, Arnaud ; Leboulleux, Sophie ; Guerin, Carole ; Faron, Matthieu ; Baudin, Eric</creatorcontrib><description>Abstract
Context
The behavior of locally advanced pheochromocytoma (LAP) remains unknown.
Objective
We characterized the population with LAP and recurrence-free survival (RFS).
Methods
This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence.
Results
Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis.
Conclusion
LAP represents 9% of pheochromocytoma’s population and has a metastatic behavior. This study paves the way for future pathological TNM classification.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/clinem/dgab202</identifier><identifier>PMID: 33782697</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adipose tissue ; Adipose tissues ; Catecholamines ; Gene mutations ; Human health and pathology ; Invasions ; Life Sciences ; Lymph nodes ; Lymphatic system ; Medical prognosis ; Metastases ; Metastasis ; Multivariate analysis ; Pheochromocytoma ; Survival ; Survival analysis</subject><ispartof>The journal of clinical endocrinology and metabolism, 2021-09, Vol.106 (9), p.2726-2737</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>COPYRIGHT 2021 Oxford University Press</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-9232ef29c4123fe4a11ad3c685b5874f7ef3b083ed9c76c46ac2ca84f1d59bfc3</citedby><cites>FETCH-LOGICAL-c498t-9232ef29c4123fe4a11ad3c685b5874f7ef3b083ed9c76c46ac2ca84f1d59bfc3</cites><orcidid>0000-0002-2198-3582 ; 0000-0003-2515-7840 ; 0000-0003-2228-0106 ; 0000-0002-1808-8800 ; 0000-0003-3942-4276 ; 0000-0002-4816-670X ; 0000-0002-4824-8502 ; 0000-0002-4247-3039</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33782697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://amu.hal.science/hal-03662818$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Moog, Sophie</creatorcontrib><creatorcontrib>Castinetti, Frédéric</creatorcontrib><creatorcontrib>DoCao, Christine</creatorcontrib><creatorcontrib>Amar, Laurence</creatorcontrib><creatorcontrib>Hadoux, Julien</creatorcontrib><creatorcontrib>Lussey-Lepoutre, Charlotte</creatorcontrib><creatorcontrib>Borson-Chazot, Françoise</creatorcontrib><creatorcontrib>Vezzosi, Delphine</creatorcontrib><creatorcontrib>Drui, Delphine</creatorcontrib><creatorcontrib>Laboureau, Sandrine</creatorcontrib><creatorcontrib>Raffin Sanson, Marie-Laure</creatorcontrib><creatorcontrib>Lamartina, Livia</creatorcontrib><creatorcontrib>Pierre, Peggy</creatorcontrib><creatorcontrib>Batisse Ligner, Marie</creatorcontrib><creatorcontrib>Hescot, Ségolène</creatorcontrib><creatorcontrib>Al Ghuzlan, Abir</creatorcontrib><creatorcontrib>Renaudin, Karine</creatorcontrib><creatorcontrib>Libé, Rosella</creatorcontrib><creatorcontrib>Laroche, Suzanne</creatorcontrib><creatorcontrib>Deniziaut, Gabrielle</creatorcontrib><creatorcontrib>Gimenez-Roqueplo, Anne-Paule</creatorcontrib><creatorcontrib>Jannin, Arnaud</creatorcontrib><creatorcontrib>Leboulleux, Sophie</creatorcontrib><creatorcontrib>Guerin, Carole</creatorcontrib><creatorcontrib>Faron, Matthieu</creatorcontrib><creatorcontrib>Baudin, Eric</creatorcontrib><title>Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Abstract
Context
The behavior of locally advanced pheochromocytoma (LAP) remains unknown.
Objective
We characterized the population with LAP and recurrence-free survival (RFS).
Methods
This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence.
Results
Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis.
Conclusion
LAP represents 9% of pheochromocytoma’s population and has a metastatic behavior. This study paves the way for future pathological TNM classification.</description><subject>Adipose tissue</subject><subject>Adipose tissues</subject><subject>Catecholamines</subject><subject>Gene mutations</subject><subject>Human health and pathology</subject><subject>Invasions</subject><subject>Life Sciences</subject><subject>Lymph nodes</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Pheochromocytoma</subject><subject>Survival</subject><subject>Survival analysis</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqF0c-L1DAUB_AiijuuXj1KwYseuptfzQ9vZXFcYUDxB3oLafqykyVtukk7MP-9HWZcRRYkh8Dj8x7J-xbFS4wuMMHo0gY_QH_Z3ZiWIPKoWGHF6kpgJR4XK4QIrpQgP8-KZznfIoQZq-nT4oxSIQlXYlX8-AJ2TgkGC9U6AZRf57TzOxPKZjBhn30u_VBuojUh7Mum25lFduXnLUS7TbGPdj_F3rwr1z7lqWzGMRmfTXhePHEmZHhxus-L7-v3366uq82nDx-vmk1lmZJTpQgl4IiyDBPqgBmMTUctl3VbS8GcAEdbJCl0ygpuGTeWWCOZw12tWmfpefH2OHdrgh6T703a62i8vm42-lBDlHMisdzhxb452jHFuxnypHufLYRgBohz1qRGAjNOqVzo63_obZzTspFFqZpjilT9l7oxAbQfXJySsYehuuFS8hoLrhZ18YBaTge9t3EA55f6Qw02xZwTuPuPYaQPqetj6vqU-tLw6vTaue2hu-e_Y_6zpTiP_xv2C5lwtkg</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Moog, Sophie</creator><creator>Castinetti, Frédéric</creator><creator>DoCao, Christine</creator><creator>Amar, Laurence</creator><creator>Hadoux, Julien</creator><creator>Lussey-Lepoutre, Charlotte</creator><creator>Borson-Chazot, Françoise</creator><creator>Vezzosi, Delphine</creator><creator>Drui, Delphine</creator><creator>Laboureau, Sandrine</creator><creator>Raffin Sanson, Marie-Laure</creator><creator>Lamartina, Livia</creator><creator>Pierre, Peggy</creator><creator>Batisse Ligner, Marie</creator><creator>Hescot, Ségolène</creator><creator>Al Ghuzlan, Abir</creator><creator>Renaudin, Karine</creator><creator>Libé, Rosella</creator><creator>Laroche, Suzanne</creator><creator>Deniziaut, Gabrielle</creator><creator>Gimenez-Roqueplo, Anne-Paule</creator><creator>Jannin, Arnaud</creator><creator>Leboulleux, Sophie</creator><creator>Guerin, Carole</creator><creator>Faron, Matthieu</creator><creator>Baudin, Eric</creator><general>Oxford University Press</general><general>Endocrine Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-2198-3582</orcidid><orcidid>https://orcid.org/0000-0003-2515-7840</orcidid><orcidid>https://orcid.org/0000-0003-2228-0106</orcidid><orcidid>https://orcid.org/0000-0002-1808-8800</orcidid><orcidid>https://orcid.org/0000-0003-3942-4276</orcidid><orcidid>https://orcid.org/0000-0002-4816-670X</orcidid><orcidid>https://orcid.org/0000-0002-4824-8502</orcidid><orcidid>https://orcid.org/0000-0002-4247-3039</orcidid></search><sort><creationdate>20210901</creationdate><title>Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal</title><author>Moog, Sophie ; Castinetti, Frédéric ; DoCao, Christine ; Amar, Laurence ; Hadoux, Julien ; Lussey-Lepoutre, Charlotte ; Borson-Chazot, Françoise ; Vezzosi, Delphine ; Drui, Delphine ; Laboureau, Sandrine ; Raffin Sanson, Marie-Laure ; Lamartina, Livia ; Pierre, Peggy ; Batisse Ligner, Marie ; Hescot, Ségolène ; Al Ghuzlan, Abir ; Renaudin, Karine ; Libé, Rosella ; Laroche, Suzanne ; Deniziaut, Gabrielle ; Gimenez-Roqueplo, Anne-Paule ; Jannin, Arnaud ; Leboulleux, Sophie ; Guerin, Carole ; Faron, Matthieu ; Baudin, Eric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-9232ef29c4123fe4a11ad3c685b5874f7ef3b083ed9c76c46ac2ca84f1d59bfc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adipose tissue</topic><topic>Adipose tissues</topic><topic>Catecholamines</topic><topic>Gene mutations</topic><topic>Human health and pathology</topic><topic>Invasions</topic><topic>Life Sciences</topic><topic>Lymph nodes</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Pheochromocytoma</topic><topic>Survival</topic><topic>Survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moog, Sophie</creatorcontrib><creatorcontrib>Castinetti, Frédéric</creatorcontrib><creatorcontrib>DoCao, Christine</creatorcontrib><creatorcontrib>Amar, Laurence</creatorcontrib><creatorcontrib>Hadoux, Julien</creatorcontrib><creatorcontrib>Lussey-Lepoutre, Charlotte</creatorcontrib><creatorcontrib>Borson-Chazot, Françoise</creatorcontrib><creatorcontrib>Vezzosi, Delphine</creatorcontrib><creatorcontrib>Drui, Delphine</creatorcontrib><creatorcontrib>Laboureau, Sandrine</creatorcontrib><creatorcontrib>Raffin Sanson, Marie-Laure</creatorcontrib><creatorcontrib>Lamartina, Livia</creatorcontrib><creatorcontrib>Pierre, Peggy</creatorcontrib><creatorcontrib>Batisse Ligner, Marie</creatorcontrib><creatorcontrib>Hescot, Ségolène</creatorcontrib><creatorcontrib>Al Ghuzlan, Abir</creatorcontrib><creatorcontrib>Renaudin, Karine</creatorcontrib><creatorcontrib>Libé, Rosella</creatorcontrib><creatorcontrib>Laroche, Suzanne</creatorcontrib><creatorcontrib>Deniziaut, Gabrielle</creatorcontrib><creatorcontrib>Gimenez-Roqueplo, Anne-Paule</creatorcontrib><creatorcontrib>Jannin, Arnaud</creatorcontrib><creatorcontrib>Leboulleux, Sophie</creatorcontrib><creatorcontrib>Guerin, Carole</creatorcontrib><creatorcontrib>Faron, Matthieu</creatorcontrib><creatorcontrib>Baudin, Eric</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moog, Sophie</au><au>Castinetti, Frédéric</au><au>DoCao, Christine</au><au>Amar, Laurence</au><au>Hadoux, Julien</au><au>Lussey-Lepoutre, Charlotte</au><au>Borson-Chazot, Françoise</au><au>Vezzosi, Delphine</au><au>Drui, Delphine</au><au>Laboureau, Sandrine</au><au>Raffin Sanson, Marie-Laure</au><au>Lamartina, Livia</au><au>Pierre, Peggy</au><au>Batisse Ligner, Marie</au><au>Hescot, Ségolène</au><au>Al Ghuzlan, Abir</au><au>Renaudin, Karine</au><au>Libé, Rosella</au><au>Laroche, Suzanne</au><au>Deniziaut, Gabrielle</au><au>Gimenez-Roqueplo, Anne-Paule</au><au>Jannin, Arnaud</au><au>Leboulleux, Sophie</au><au>Guerin, Carole</au><au>Faron, Matthieu</au><au>Baudin, Eric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>106</volume><issue>9</issue><spage>2726</spage><epage>2737</epage><pages>2726-2737</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Abstract
Context
The behavior of locally advanced pheochromocytoma (LAP) remains unknown.
Objective
We characterized the population with LAP and recurrence-free survival (RFS).
Methods
This retrospective multicentric study was run within the ENDOCAN-COMETE network and French Group of Endocrine Tumors (GTE) from 2003 to 2018, including patients from 11 French referral centers with LAP as defined by capsular invasion, vascular invasion, adipose tissue invasion, and/or positive locoregional lymph nodes at diagnosis without evidence of distant metastasis. The main outcome measure was recurrence, defined as tumor reappearance, including local site and/or distant metastasis. The primary endpoint was RFS analysis; secondary endpoints were characterization, overall survival (OS), and prognostic factors of recurrence.
Results
Among 950 patients, 90 (9%) exhibited LAP criteria and 55 met inclusion criteria (median age, 53 years; 61% males; 14% with germline mutation; 84% with catecholamine excess). LAP was defined by 31 (56%) capsular invasions, 27 (49%) fat invasions, 6 (11%) positive lymph nodes, and 22 (40%) vascular invasions. After median follow-up of 54 months (range, 6-180), 12 patients (22%) had recurrences and 3 (5%) died of metastatic disease. Median RFS was 115 months (range, 6-168). Recurrences were local in 2 patients, distant in 2, and both local and distant in 8 patients. Median OS of patients was not reached. Size above 6.5 cm (P = 0.019) and Ki-67 > 2% (P = 0.028) were identified as independent significant prognostic factors in multivariate analysis.
Conclusion
LAP represents 9% of pheochromocytoma’s population and has a metastatic behavior. This study paves the way for future pathological TNM classification.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>33782697</pmid><doi>10.1210/clinem/dgab202</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2198-3582</orcidid><orcidid>https://orcid.org/0000-0003-2515-7840</orcidid><orcidid>https://orcid.org/0000-0003-2228-0106</orcidid><orcidid>https://orcid.org/0000-0002-1808-8800</orcidid><orcidid>https://orcid.org/0000-0003-3942-4276</orcidid><orcidid>https://orcid.org/0000-0002-4816-670X</orcidid><orcidid>https://orcid.org/0000-0002-4824-8502</orcidid><orcidid>https://orcid.org/0000-0002-4247-3039</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2021-09, Vol.106 (9), p.2726-2737 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03662818v1 |
| source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adipose tissue Adipose tissues Catecholamines Gene mutations Human health and pathology Invasions Life Sciences Lymph nodes Lymphatic system Medical prognosis Metastases Metastasis Multivariate analysis Pheochromocytoma Survival Survival analysis |
| title | Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T01%3A25%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recurrence-Free%20Survival%20Analysis%20in%20Locally%20Advanced%20Pheochromocytoma:%20First%20Appraisal&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Moog,%20Sophie&rft.date=2021-09-01&rft.volume=106&rft.issue=9&rft.spage=2726&rft.epage=2737&rft.pages=2726-2737&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/clinem/dgab202&rft_dat=%3Cgale_hal_p%3EA688651769%3C/gale_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2956130958&rft_id=info:pmid/33782697&rft_galeid=A688651769&rft_oup_id=10.1210/clinem/dgab202&rfr_iscdi=true |